Skip to content
Menu

BeOne Medicines AG ONC

Full chart Compare
Set alert

Price alert · ONC

All alert types
395.35 USD -4.35 (-1.09%)

As ofNov 20, 2026, 12:19 PM EST

385.00 Day range 399.76
253.95 52-week range 424.73
YTD
+30.13%
1 year
+13.19%

5D -20.77 (-4.97%)

400410420MonTueWedThuFri397.00
Market cap
45.14B
Revenue (ttm)
6.61B
Profit margin
13.86%
EPS (ttm)
7.80
Shares out
105.38M
P/E ratio
50.66
Forward P/E
37.07
YTD return
+30.13%
1-year return
+13.19%
50-day average
372.52
Volume
193.24K
Avg volume
391.11K
Open
386.44
Previous close
399.70
Day's range
385.00 – 399.76
52-week range
253.95 – 424.73
Beta
0.63
Analysts
Strong Buy
Price target
470.52 (+19.0%)
Earnings date
Feb 25, 2027

Key statistics

200-day average
328.78
Enterprise value
42.38B
PEG ratio
0.71
Price / sales
6.91
Price / book
7.84
Revenue growth
33.80%
Free cash flow
1.03B
Total cash
5.78B
Total debt
2.06B
Return on equity
18.40%
Short % of float
1.97%

Fundamental scorecard

15 of 25 checks passed on ONC’s reported financials

ValueGrowthProfitabilityHealthDividend

15of 25 checks passed

  • Value 1 of 5
  • Growth 5 of 5
  • Profitability 4 of 5
  • Financial health 5 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
ONC Revenue — quarterly 1.89B
ONC Net income — quarterly 384.71M
ONC EPS — quarterly 0.26

Earnings

ONC recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 25, 2027Dec 30, 20263.99———
Nov 5, 2026Sep 30, 20262.344.59+2.25+96.15%
Aug 5, 2026Jun 30, 20261.632.05+0.42+25.77%
May 6, 2026Mar 31, 20260.731.96+1.23+168.49%
Feb 26, 2026Dec 31, 20251.600.58-1.02-63.75%
Nov 6, 2025Sep 30, 20250.721.09+0.37+51.39%

Upgrades / downgrades

ONC analyst upgrades and downgrades
DateFirmActionFromTo
Nov 6, 2026RBC CapitalmainOutperformOutperform
Nov 6, 2026Truist SecuritiesreitBuyBuy
Nov 6, 2026BarclaysmainOverweightOverweight
Nov 6, 2026CitizensmainMarket OutperformMarket Outperform
Nov 6, 2026Wells FargomainOverweightOverweight
Oct 8, 2026RBC CapitalmainOutperformOutperform

About BeOne Medicines AG

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. The company has a agreement with U.S. government to expand access to innovative cancer medicines. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.

Sector
Healthcare
Industry
Biotechnology
Country
Switzerland

News

Your note

Sign in to keep a note on ONC — it syncs with the Stock Master app.

Insider holders

ONC insider holders
InsiderRelationLatest transactionDateShares held
BAKER BROS ADVISORS L.P.UnknownSaleDec 8, 20240
BAKER BROTHERS LIFE SCIENCES, L.P.UnknownSaleFeb 27, 20250
BALL TITUS BENJAMINOfficerSaleNov 5, 20260
DUGAN MARGARETDirectorSaleMay 21, 20260
LEE CHAN HENRYGeneral CounselSaleNov 4, 20260
RIVA ALESSANDRODirectorSaleMay 21, 20260

Institution ownership

ONC institution ownership
Holder% heldSharesValueReported
Baker Bros. Advisors, LP8.04%8,832,3353.53BSep 29, 2026
Primecap Management Company4.47%4,906,7011.96BSep 29, 2026
Capital International Investors4.20%4,608,9091.84BSep 29, 2026
Capital World Investors3.55%3,902,3191.56BSep 29, 2026
FMR, LLC2.11%2,321,959928.09MSep 29, 2026
Blackrock Inc.0.73%804,086321.39MSep 29, 2026

Fund ownership

ONC fund ownership
Holder% heldSharesValueReported
NEW PERSPECTIVE FUND2.76%3,035,5001.21BSep 29, 2026
VANGUARD CHESTER FUNDS-Vanguard PRIMECAP Fund2.14%2,347,622938.34MJun 29, 2026
VANGUARD HORIZON FUNDS-Vanguard Capital Opportunity Fund1.08%1,182,071472.47MJun 29, 2026
New Economy Fund0.89%972,969388.90MSep 29, 2026
AMERICAN FUNDS FUNDAMENTAL INVESTORS0.74%808,969323.34MSep 29, 2026
New World Fund Inc0.65%710,365283.93MSep 29, 2026